0.6674
price down icon1.52%   -0.0077
 
loading

Zyversa Therapeutics Inc 주식(ZVSA)의 최신 뉴스

pulisher
08:50 AM

Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation - marketscreener.com

08:50 AM
pulisher
07:58 AM

ZyVersa Therapeutics Announces Published Data Showing - GlobeNewswire

07:58 AM
pulisher
07:57 AM

Game-Changing Parkinson's Treatment: Nature Study Reveals Drug's Dual-Action Against Disease Progression - Stock Titan

07:57 AM
pulisher
Apr 24, 2025

ZyVersa progresses with novel inflammation treatment - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

ZyVersa progresses with novel inflammation treatment By Investing.com - Investing.com UK

Apr 24, 2025
pulisher
Apr 24, 2025

ZyVersa Therapeutics CEO Issues Shareholder Letter - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

ZyVersa's IC 100 Drug Targets $186B Market, Sets 2025 Clinical Timeline | ZVSA Stock News - Stock Titan

Apr 24, 2025
pulisher
Apr 22, 2025

ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders - MSN

Apr 22, 2025
pulisher
Apr 17, 2025

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Drop in Short Interest - Defense World

Apr 17, 2025
pulisher
Apr 10, 2025

Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

10 Stocks Fall Behind Amid Market Optimism - Insider Monkey

Apr 10, 2025
pulisher
Apr 09, 2025

ZyVersa CEO outlines progress in kidney disease drug development - Investing.com

Apr 09, 2025
pulisher
Apr 08, 2025

ZyVersa Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa CEO outlines progress in kidney disease drug development By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa Therapeutics (ZVSA) Highlights Potential of IC 100 for O - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa Therapeutics (ZVSA) Reports 2024 Financial Results and P - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa Therapeutics (ZVSA) Secures $2 Million Through Securitie - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa CEO issues shareholder letter on PARASOL recommendations - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewswire

Apr 08, 2025
pulisher
Apr 07, 2025

ZyVersa Therapeutics appoints new accounting firm - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

ZyVersa Therapeutics appoints new accounting firm By Investing.com - Investing.com India

Apr 07, 2025
pulisher
Apr 04, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Apr 04, 2025
pulisher
Apr 02, 2025

ZVSA stock touches 52-week low at $0.58 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

ZVSA stock touches 52-week low at $0.58 amid sharp annual decline - Investing.com Australia

Apr 02, 2025
pulisher
Apr 02, 2025

Virtu Financial LLC Purchases Shares of 25,259 ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) - Defense World

Apr 02, 2025
pulisher
Mar 27, 2025

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

ZyVersa Slashes Annual Losses by 90% While Pushing Forward With Crucial Kidney Disease Drug Trial - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update - Defense World

Mar 27, 2025
pulisher
Mar 25, 2025

ZVSA stock touches 52-week low at $0.69 amid market challenges - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

ZVSA stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 24, 2025

ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Keros Therapeutics (NASDAQ:KROS) Financial Analysis - Defense World

Mar 24, 2025
pulisher
Mar 19, 2025

ZyVersa’s IC 100 shows promise in OAC treatment study By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

ZyVersa’s IC 100 shows promise in OAC treatment study - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association ... - The Bakersfield Californian

Mar 18, 2025
pulisher
Mar 18, 2025

ZyVersa Therapeutics Highlights Data Published in the - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - TradingView

Mar 18, 2025
pulisher
Mar 17, 2025

Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail

Mar 17, 2025
pulisher
Mar 17, 2025

ZyVersa Therapeutics (ZVSA) Expected to Announce Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 14, 2025

Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Declines By 54.6% - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

ZVSA stock touches 52-week low at $0.8 amid sharp annual decline - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

ZVSA stock touches 52-week low at $0.8 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

ZyVersa’s Alzheimer’s treatment shows promise in studies By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

ZyVersa’s Alzheimer’s treatment shows promise in studies - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

ZyVersa Therapeutics Highlights Data Demonstrating - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model - The Manila Times

Mar 12, 2025
pulisher
Mar 12, 2025

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

ZyVersa: Preclinical Data Supports Potential Of IC 100 Against Alzheimer's, Parkinsons - Nasdaq

Mar 12, 2025
pulisher
Mar 07, 2025

ZyVersa secures $2 million in funding for drug development By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 06, 2025

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

ZyVersa Therapeutics announces pricing of $2M private placement - MSN

Mar 06, 2025
pulisher
Mar 06, 2025

ZyVersa secures $2 million in funding for drug development - Investing.com

Mar 06, 2025
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
자본화:     |  볼륨(24시간):